Watanabe, Hideaki
Bristol-Myers Squibb (United States)
3 papers on CoChatORCID 0000-0002-9367-5167
Most cited papers
- Verified
Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments
Cited by 70
- Verified
Naringenin suppresses macrophage infiltration into adipose tissue in an early phase of high-fat diet-induced obesity
Yoshida, H., Watanabe, H., Ishida, A., Watanabe, W., Narumi, K., Atsumi, T., Sugita, C., & Kurokawa, M. (2014) · Biochemical and Biophysical Research Communications
Adipokines, Inflammation, and Metabolic DiseasesFlavonoids in Medical Research
Cited by 66
- Verified
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases
Cited by 59
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free